DPhil - University of Oxford (2025)

MRCP (Neuro) - Royal College of Physicians (2024)

MRCP (UK) - Royal College of Physicians (2018)

AFHEA - Higher Education Academy (2018)

MBBS (Hons) - University of Turin, Italy (2014)

Open to approach for:

- DPhil projects 

- Grant writing and funding applications

- Clinical Academic Trainees

- MSc/FSH student projects

I am an Academic Clinical Lecturer in Neurology at the University of Oxford and an Honorary Neurology Registrar at Oxford University Hospitals. I completed my DPhil at the University of Oxford and UCL Queen Square, funded by an MRC Clinical Research Training Fellowship and a Brain Predoctoral Research Fellowship. I previously undertook my clinical training in Cambridge, the East of England, and London (National Hospital for Neurology and Neurosurgery).

Fluid biomarkers 

My research focuses on translational biomarker discovery, ultrasensitive assay development, and stem cell-based modelling of peripheral nerve disease. Using single molecule array (Simoa) technology, I developed the first ultrasensitive immunoassay to measure periaxin, a protein exclusively expressed in the peripheral nervous system (PNS). A reliable fluid biomarker of peripheral demyelination has long been sought, but previous candidates have lacked the specificity or robustness required for clinical use. Periaxin represents the first PNS-specific biomarker with the potential to improve diagnosis and monitoring of demyelinating neuropathies, particularly when combined with axonal biomarkers and clinical scales. It also holds promise as a surrogate endpoint to enhance the design and efficiency of early-phase clinical trials.

I have established the first peripheral neuropathy fluid biomarker panel, including periaxin, peripherin (an axonal intermediate filament predominantly expressed in the PNS), and neurofilament light chain (NfL). Together, these biomarkers are being evaluated for their utility in diagnosis, disease monitoring, and prognosis.

My experimental work combines in vitro models of antibody-mediated, complement-dependent cell injury with analyses of blood samples (plasma and serum) from patients with inflammatory neuropathies.

This work has led to international collaborations across Europe and North America, as well as prospective partnerships with the pharmaceutical industry. Locally, collaborations within the Nuffield Department of Clinical Neurosciences and University College London (Queen Square) are advancing the integration into translational neuromuscular research. I lead studies aimed at applying these biomarkers across broader disease cohorts in longitudinal settings, defining clinically meaningful thresholds, and establishing disease-specific biomarker profiles to support precision diagnosis and therapy in peripheral neuropathy.

Clinical trials

I am a sub-investigator in two international clinical trials investigating novel immunotherapies for immune-mediated neuropathies, including neonatal Fc Receptor (FcRn) blockade in chronic inflammatory demyelinating polyneuropathy (CIDP) and complement inhibition in multifocal motor neuropathy (MMN).